X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding X4 Pharmaceuticals, Inc changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 59 | 2 | 54 | −3 |
| Shares | 39.1M | 317.7K | 60.6M | +21.8M (+56.2%) |
| Value | $66.9M | $542.7K | $60.2M | −$6.17M (−9.3%) |
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CVI Holdings, LLC | 2,381,923 | $2.37M | 0.30% |
| Lynwood Capital Management Inc. | 2,155,100 | $2.14M | 2.58% |
| Ghost Tree Capital, LLC | 1,000,000 | $993.0K | 0.42% |
| Citadel Advisors LLC | 944,853 | $938.2K | 0.00% |
| Schonfeld Strategic Advisors LLC | 895,300 | $889.0K | 0.01% |
| JPMorgan Chase & Co | 119,598 | $119.0K | 0.00% |
| Commonwealth Equity Services, LLC | 22,500 | $22.0K | 0.00% |
| Two Sigma Investments, LP | 22,102 | $21.9K | 0.00% |
| Invesco Ltd. | 15,614 | $15.5K | 0.00% |
| Tower Research Capital LLC (TRC) | 10,227 | $10.0K | 0.00% |
Sold out (13)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| AIGH Capital Management LLC | 997,719 | $1.71M |
| Worth Venture Partners, LLC | 250,144 | $428.0K |
| Susquehanna International Group, LLP | 150,597 | $258.0K |
| BIT Capital GmbH | 45,000 | $77.0K |
| Kestra Advisory Services, LLC | 33,000 | $56.0K |
| Connor, Clark & Lunn Investment Management Ltd. | 23,065 | $39.0K |
| Private Advisor Group, LLC | 13,221 | $23.0K |
| FMR LLC | 10,000 | $17.0K |
| Moody Lynn & Lieberson, LLC | 10,000 | $17.0K |
| Dynamic Advisor Solutions LLC | 10,100 | $17.0K |
| Mayflower Financial Advisors, LLC | 10,000 | $17.0K |
| UBS Group AG | 9,525 | $16.0K |
| Royal Bank of Canada | 101 | $0 |
Not filed for Q4 2022 yet (2)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| SV Health Investors, LLC | 311,490 | $532.0K |
| American Portfolios Advisors | 6,250 | $10.7K |